未登录

S

Sture Lindegren

Institute of Clinical Sciences

H指数:27

被引数:2,291

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Solving the limited availability of Astatine-211 from a European perspective: from production to the end user

从欧洲视角解决砹-211供应有限的问题：从生产到最终用户

EJNMMI Radiopharmacy and Chemistry

IF3.3

2026-02-170

OAAI

Radiolabeling yield dependency of post-dry distillation decay of astatine-211

211-statine的干馏后衰减的放射性标记产率依赖性

NUCLEAR MEDICINE AND BIOLOGY

IF3

2025-05-010

PRE

Behaviour, use and safety aspects of astatine-211 solvated in chloroform after dry distillation recovery

SCIENTIFIC REPORTS

IF3.9

2024-04-271

OAAI

Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted a-Therapy of Prostate Cancer

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2024-02-294

OA

Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211

PHARMACEUTICALS

IF4.8

2023-04-1511

OAAI

Astatine-211 based radionuclide therapy: Current clinical trial landscape

FRONTIERS IN MEDICINE

IF3

2023-01-0638

OAAI

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2022-07-074

OAAI

Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors

EJNMMI RESEARCH

IF3

2020-02-1120

OAAI

Towards elucidating the radiochemistry of astatine - Behavior in chloroform

SCIENTIFIC REPORTS

IF3.9

2019-11-0413

OAAI

Intraperitoneal α-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2019-01-2548

OAAI

Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2017-11-248

OAAI

Formation of DNA double-strand breaks in colon tumors after targeted alpha therapy with 211At-mAb

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model

EJNMMI RESEARCH

IF3

2017-04-2418

OAAI

Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with 211At-MX35-F(ab')2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2016-09-2920

OAAI

Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates

BIOCONJUGATE CHEMISTRY

IF3.9

2016-01-2922

PREAI

Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2016-01-1419

OAAI

Absorbed Doses and Risk Estimates of 211At-MX35 F(ab′)2 in Intraperitoneal Therapy of Ovarian Cancer Patients

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

IF6.5

2015-11-0143

PREAI

Automated astatination of biomolecules - a stepping stone towards multicenter clinical trials

SCIENTIFIC REPORTS

IF3.9

2015-07-1437

OAAI

A radio-high-performance liquid chromatography dual-flow cell gamma-detection system for on-line radiochemical purity and labeling efficiency determination

JOURNAL OF CHROMATOGRAPHY A

IF4

2014-04-0110

PREAI

Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the α-Camera Technique

JOURNAL OF NUCLEAR MEDICINE

IF9.1

2013-06-1224

OAAI